These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28271416)

  • 1. Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura.
    Suntsova EV; Demina IM; Ignatova AA; Ershov NM; Trubina NM; Dobrynina J; Serkova IV; Supik ZS; Orekhova EV; Hachatryan LA; Kotskaya NN; Pshonkin AV; Maschan AA; Novichkova GA; Panteleev MA
    Int J Hematol; 2017 Jun; 105(6):841-848. PubMed ID: 28271416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of eltrombopag after romiplostim in primary immune thrombocytopenia.
    González-Porras JR; Mingot-Castellano ME; Andrade MM; Alonso R; Caparrós I; Arratibel MC; Fernández-Fuertes F; Cortti MJ; Pascual C; Sánchez-González B; Bernat S; Fuertes-Palacio MA; Vázquez-Paganini JA; Olivera PE; Alvarez-Román MT; Jarque I; Cortés M; Martínez-Robles V; Díaz-Gálvez FJ; Calbacho M; Fernández-Miñano C; Garcia-Frade J; González-López TJ
    Br J Haematol; 2015 Apr; 169(1):111-6. PubMed ID: 25521630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
    D'Arena G; Guariglia R; Mansueto G; Martorelli MC; Pietrantuono G; Villani O; Lerose R; Musto P
    Blood; 2013 Feb; 121(7):1240-2. PubMed ID: 23411736
    [No Abstract]   [Full Text] [Related]  

  • 4. Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
    Suntsova EV; Maschan AA; Baydildina DD; Kalinina II; Petrova UN; Pshonkin AV; Novichkova GA
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27704. PubMed ID: 30854783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
    Depré F; Aboud N; Mayer B; Salama A
    Blood Transfus; 2018 May; 16(3):307-312. PubMed ID: 28151387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
    Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
    Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV
    Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
    Scaramucci L; Giovannini M; Niscola P; Tendas A; Perrotti A; De Fabritiis P
    Blood Transfus; 2014 Oct; 12(4):605-7. PubMed ID: 25351191
    [No Abstract]   [Full Text] [Related]  

  • 10. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
    Kowalczyk M; Rubinstein PG; Aboulafia DM
    J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577
    [No Abstract]   [Full Text] [Related]  

  • 12. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.
    Neunert CE; Rose MJ
    Blood Adv; 2019 Jun; 3(12):1907-1915. PubMed ID: 31239245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.
    Cooper KL; Fitzgerald P; Dillingham K; Helme K; Akehurst R
    Int J Technol Assess Health Care; 2012 Jul; 28(3):249-58. PubMed ID: 22980701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
    Lakhwani S; Perera M; Fernández-Fuertes F; Ríos de Paz MA; Torres M; Raya JM; Hernández MT
    Eur J Haematol; 2017 Oct; 99(4):372-377. PubMed ID: 28759125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
    Neunert CE
    Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
    Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
    Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M; Kato M; Koh K; Hanada R
    Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.